AA Financial Advisors LLC Has $557,000 Stake in Astrazeneca Plc $AZN

AA Financial Advisors LLC lowered its position in shares of Astrazeneca Plc (NYSE:AZN) by 31.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,055 shares of the company’s stock after selling 2,774 shares during the quarter. AA Financial Advisors LLC’s holdings in Astrazeneca were worth $557,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of AZN. Triumph Capital Management acquired a new stake in Astrazeneca during the third quarter worth approximately $25,000. Rakuten Investment Management Inc. acquired a new position in Astrazeneca in the third quarter valued at approximately $31,000. JPL Wealth Management LLC acquired a new position in Astrazeneca in the third quarter valued at approximately $35,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of Astrazeneca by 144.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after buying an additional 275 shares in the last quarter. Finally, Abound Wealth Management boosted its holdings in shares of Astrazeneca by 1,767.9% during the 3rd quarter. Abound Wealth Management now owns 523 shares of the company’s stock worth $40,000 after buying an additional 495 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Astrazeneca Stock Up 0.1%

Shares of NYSE:AZN opened at $188.57 on Monday. Astrazeneca Plc has a twelve month low of $122.48 and a twelve month high of $212.71. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. The company has a market cap of $292.45 billion, a PE ratio of 32.48, a PEG ratio of 1.42 and a beta of 0.32.

Astrazeneca Announces Dividend

The firm also recently disclosed a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were issued a dividend of $1.595 per share. This represents a dividend yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s dividend payout ratio (DPR) is currently 66.26%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AZN shares. Citigroup assumed coverage on shares of Astrazeneca in a research note on Tuesday, January 27th. They issued a “buy” rating for the company. Weiss Ratings initiated coverage on shares of Astrazeneca in a research note on Wednesday, March 11th. They set a “buy (b)” rating on the stock. TD Cowen restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. Finally, HSBC reiterated a “buy” rating and set a $108.00 price objective on shares of Astrazeneca in a report on Wednesday, December 10th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

Key Headlines Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late‑stage trial win — Tozorakimab met primary goals in two pivotal trials, reducing chronic obstructive pulmonary disease flare‑ups versus placebo; the surprise positive readout is driving optimism about near‑term commercialization potential and pipeline momentum. AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
• Positive Sentiment: Regulatory and commercial implications — Reuters and other outlets highlight the meaningful reduction in flare‑ups and the significance of a successful phase III outcome for a disease area where competitors have struggled, which increases the drug’s value on AstraZeneca’s roadmap. AstraZeneca drug reduces COPD flare ups in late-stage trials
• Positive Sentiment: Clinical confirmation across endpoints — The Wall Street Journal and other reports emphasize that the trials hit their primary endpoints by lowering symptom worsening rates, reinforcing confidence in the data’s robustness and the potential for label and payer discussions. AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
• Neutral Sentiment: Stock movement vs. market — Coverage notes AZN advanced while broader markets were down, indicating the move is company‑specific (trial news/pipeline) rather than market driven. Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
• Neutral Sentiment: Analyst positioning — AstraZeneca has a consensus analyst rating of “Moderate Buy,” which supports the stock’s upside but does not by itself explain today’s move; analyst views may follow as investigators and investors digest full data and commercial assumptions. Astrazeneca Plc (NYSE:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.